SIOBHAN YOSHIDA: Open Payments
NPI 1881883205 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,323 in 68 payments from 19 companies in 2025. Trend: 2023 $1,211 · 2024 $1,424 · 2025 $1,323
Food & beverage: $1,323
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 8 | $236 |
| ABBVIE INC. | 10 | $193 |
| Novo Nordisk Inc | 10 | $175 |
| PFIZER INC. | 6 | $108 |
| Lilly USA, LLC | 7 | $98 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $93 |
| Abbott Laboratories | 3 | $67 |
| Merck Sharp & Dohme LLC | 3 | $57 |
| Corcept Therapeutics | 2 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
Products named: Veozah, VRAYLAR, Ozempic, Kerendia, PREVNAR 20, FREESTYLE LIBRE 3, MOUNJARO, Korlym.
Industry payments across MD — which companies pay providers there.
